oxalidine
Phase 3Small molecule
oxalidine is one of 10 small molecule programs targeting Multimodal Analgesia. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
9 competitors in Multimodal Analgesia
#DrugCompanyPhaseTrials
1Tylenol
KKenvue Brands
Approved
Neurontin
VViatris Specialty LLC
Approved
Celebrex
PPhiladelphia Eye Associates
Approved
oxalidine
YYongtao Sun
Phase 3
Acupan
YYonsei University
Preclinical
Valium
Akero TherapeuticsPreclinical
Dexketoprofen Trometamol
MenariniPreclinical
Celebrex
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Imovane
TTaisho Pharmaceutical Co., Ltd.
Preclinical
Naprosyn
LLogical Therapeutics
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for oxalidine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- YYongtao Sun